Zogenix to Release First Quarter 2021 Financial Results and Host Conference Call and Webcast on May 6
Zogenix, a biopharmaceutical company focused on rare disease therapies, will announce its Q1 2021 financial results on May 6, 2021, at 4:30 PM ET. The company is known for its FDA-approved therapy, FINTEPLA, for Dravet syndrome and has additional late-stage programs in rare epilepsies and mitochondrial disorders. The call will also include updates on ongoing developments and potential future studies.
- Zogenix's FINTEPLA has FDA approval for Dravet syndrome, signaling a strong market presence.
- The company is advancing two late-stage development programs in rare diseases, expanding its pipeline.
- None.
EMERYVILLE, Calif., April 22, 2021 (GLOBE NEWSWIRE) -- Zogenix (NASDAQ: ZGNX), a global biopharmaceutical company developing rare disease therapies, today announced that it will report its financial results for the first quarter ended March 31, 2021 and host a corporate update conference call and webcast after the market close on Thursday, May 6, 2021, at 4:30 PM Eastern Time.
| Conference Call Details | |
| Thursday, May 6, at 4:30 PM Eastern Time / 1:30 PM Pacific Time | |
| Toll Free: | 877-846-2690 |
| International: | 416-981-9029 |
| Conference ID: | 21993693 |
| Webcast: | http://public.viavid.com/index.php?id=144590 |
About Zogenix
Zogenix is a global biopharmaceutical company committed to developing and commercializing therapies with the potential to transform the lives of patients and their families living with rare diseases. The company’s first rare disease therapy, FINTEPLA® (fenfluramine) oral solution, has been approved by the U.S. FDA and the European Medicines Agency and is in development in Japan for the treatment of seizures associated with Dravet syndrome, a rare, severe lifelong epilepsy. The company has two additional late-stage development programs, one in a rare epilepsy called Lennox-Gastaut syndrome and one in a mitochondrial disease called TK2 deficiency. Zogenix plans to initiate a study of FINTEPLA in a genetic epilepsy called CDKL5 Deficiency Disorder (CDD) and is also collaborating with Tevard Biosciences to identify and develop potential next-generation gene therapies for Dravet syndrome and other genetic epilepsies.
CONTACTS:
Zogenix
Melinda Baker
Senior Director, Corporate Communications
+1 (510) 788-8732 | corpcomms@zogenix.com
Investors
Brian Ritchie
Managing Director, LifeSci Advisors LLC
+1 (212) 915-2578 | britchie@lifesciadvisors.com
Media
Stefanie Tuck, Vice President, Porter Novelli
+1 (978) 390-1394 | stefanie.tuck@porternovelli.com
FAQ
When will Zogenix report its Q1 2021 financial results?
What is the focus of Zogenix's development programs?
What is FINTEPLA used to treat?
How can I access Zogenix's conference call?
